SymBio Pharmaceuticals (TSE:4582) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4582 SymBio Pharmaceuticals Ltd TSE:4582
36 GF Score
Price 円69.00
GF Value 円59.96
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

TSE:4582
36GF Score
SymBio Pharmaceuticals Ltd TSE:4582
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of 円69.00 is trading 15.1% above its estimated GF Value™ of 円59.96. GuruFocus considers SymBio Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for TSE:4582:

  • Interest Received:
  • GF Value™: 円59.96 vs. price of 円69.00 (15.1% above fair value)
  • GF Score™: 36/100 with 6 warning signs

No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SymBio Pharmaceuticals Business Description

Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
36GF Score

Get the complete analysis for TSE:4582

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円69.00
Price
円59.96
GF Value